Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating intravitreal KSI-301 for non-proliferative diabetic retinopathy was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-proliferative Diabetic Retinopathy

Drugs mentioned

• KSI-301 (KSI-301)

Snippet

Sponsor: Kodiak Sciences Inc | Conditions: Non-proliferative Diabetic Retinopathy | Phase 3 | Status: TERMINATED | Results posted: 2024-09-05